Education as a predictor of liver testing behaviour: Insights from a large-scale MASLD awareness survey in India
PLOS One · 2025
DOI: 10.1371/journal.pone.0335857 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Kanica Kaushal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research and Epidemiology, Institute of Liver and Biliary Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Health Knowledge, Attitudes, Practice, Fatty Liver. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing public health concern, yet awareness remains low. This study aimed to assess MASLD awareness and identify predictors of liver testing behavior in Jaipur, India.
Methods
A cross-sectional survey of 2,102 adults was conducted from October 2023 to March 2024. Participants completed a questionnaire assessing liver health knowledge, awareness, and testing history. Logistic regression analyzed predictors of liver testing.
Results
Only 5.9% of participants had heard of fatty liver disease, with 94.0% completely unaware. Knowledge of liver functions was extremely low, with only 14.9% recognizing food digestion as a liver function. The liver testing rate was 1.8% overall. Education emerged as the strongest predictor of testing behavior, with graduates and above 8.35 times more likely to be tested than non-graduates (OR=8.35, 95% CI: 3.80–18.37, p < 0.001). Participants with higher liver function knowledge had dramatically higher testing rates of 12.9% versus 1.2% for those with low knowledge (OR=9.35, 95% CI: 4.2–20.8, p < 0.001). Employment status also significantly predicted testing (OR=5.42, 95% CI: 2.8–10.5, p < 0.001).
Discussion
This study reveals a catastrophic knowledge deficit regarding MASLD, with 94% of participants completely unaware of the condition. The strong association between education, knowledge, and testing behavior highlights a critical knowledge-to-action pathway. The extremely low overall testing rate (1.8%) indicates massive underutilization of liver health screening, particularly among unemployed and less educated individuals. These findings underscore the urgent need for comprehensive public health education on liver health, especially given India’s rising MASLD prevalence and young demographic profile. Targeted interventions to improve awareness and facilitate testing access among socioeconomically disadvantaged groups are essential to address this public health crisis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Clinical Research and Epidemiology, Institute of Liver and Biliary Sciences, New Delhi, India.
- Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
- Department of Community Medicine, Rajasthan University of Health Sciences (RUHS) College of Medical Sciences, Jaipur, Rajasthan, India.
- Consultant Statistics, Institute of Liver and Biliary Sciences, New Delhi, India.
ORCID-Profile: Kanica Kaushal, Priyanka Aggarwal, Siddhesh Mhatre
Zitieren
APA
Kaushal, K., Sharma, M. K., Aggarwal, P., Singh, S., Gautam, S., Tomar, A., Kumar, G., & Mhatre, S. (2025). Education as a predictor of liver testing behaviour: Insights from a large-scale MASLD awareness survey in India. PLOS One. https://doi.org/10.1371/journal.pone.0335857
Vancouver
Kaushal K, Sharma MK, Aggarwal P, Singh S, Gautam S, Tomar A, et al. Education as a predictor of liver testing behaviour: Insights from a large-scale MASLD awareness survey in India. PLOS One. 2025. doi:10.1371/journal.pone.0335857
BibTeX
@article{Kaushal2025,
author = {Kaushal, Kanica and Sharma, Manoj Kumar and Aggarwal, Priyanka and Singh, Smriti and Gautam, Sumridhi and Tomar, Anamika and Kumar, Guresh and Mhatre, Siddhesh},
title = {Education as a predictor of liver testing behaviour: Insights from a large-scale MASLD awareness survey in India},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0335857}
}
EUVIMED